Final survival analysis of NSGO-AVANOVA2/ENGOT-OV24: Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer—A randomized controlled chemotherapy-free study.

Mansoor Raza Mirza; Gitte-Betina Nyvang; Bente Lund; Rene dePont Christensen; Theresa Louise Werner; Susanne Malander; Line Bjørge; Michael J. Birrer; Maarit Anttila; Gabriel Lindahl; Sakari Hietanen; Maria Dimoula; Ulla Peen; Kristine Madsen; Anja Knudsen; Synnove Staff; Nicole Buchner Vinum; Maj Kamille Kjeldsen; Elisabeth Avall-Lundqvist; Johanna Unelma Maenpaa

doi:10.1200/JCO.2020.38.15_suppl.6012

Final survival analysis of NSGO-AVANOVA2/ENGOT-OV24: Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer—A randomized controlled chemotherapy-free study.

Mansoor Raza Mirza, Gitte-Betina Nyvang, Bente Lund, Rene dePont Christensen, Theresa Louise Werner, Susanne Malander, Line Bjørge, Michael J. Birrer, Maarit Anttila, Gabriel Lindahl, Sakari Hietanen, Maria Dimoula, Ulla Peen, Kristine Madsen, Anja Knudsen, Synnove Staff, Nicole Buchner Vinum, Maj Kamille Kjeldsen, Elisabeth Avall-Lundqvist, Johanna Unelma Maenpaa

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Original language	English
Journal	Journal of Clinical Oncology
Volume	38
Issue number	15, suppl.
Pages (from-to)	6012-6012
Number of pages	1
ISSN	0732-183X
DOIs	https://doi.org/10.1200/JCO.2020.38.15_suppl.6012
Publication status	Published - 2020
Event	2020 ASCO Annual Meeting - Duration: 29 May 2020 → 31 May 2020

Conference

Conference	2020 ASCO Annual Meeting
Period	29/05/2020 → 31/05/2020

Access to Document

10.1200/JCO.2020.38.15_suppl.6012

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

Mirza, M. R., Nyvang, G-B., Lund, B., Christensen, R. D., Werner, T. L., Malander, S., Bjørge, L., Birrer, M. J., Anttila, M., Lindahl, G., Hietanen, S., Dimoula, M., Peen, U., Madsen, K., Knudsen, A., Staff, S., Buchner Vinum, N., Kjeldsen, M. K., Avall-Lundqvist, E., & Maenpaa, J. U. (2020). Final survival analysis of NSGO-AVANOVA2/ENGOT-OV24: Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer—A randomized controlled chemotherapy-free study. Journal of Clinical Oncology, 38(15, suppl.), 6012-6012. https://doi.org/10.1200/JCO.2020.38.15_suppl.6012

Mirza, Mansoor Raza ; Nyvang, Gitte-Betina ; Lund, Bente et al. / Final survival analysis of NSGO-AVANOVA2/ENGOT-OV24 : Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer—A randomized controlled chemotherapy-free study. In: Journal of Clinical Oncology. 2020 ; Vol. 38, No. 15, suppl. pp. 6012-6012.

@article{ddfea1dad65a456695f1f26fb384765a,

title = "Final survival analysis of NSGO-AVANOVA2/ENGOT-OV24: Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer—A randomized controlled chemotherapy-free study.",

author = "Mirza, {Mansoor Raza} and Gitte-Betina Nyvang and Bente Lund and Christensen, {Rene dePont} and Werner, {Theresa Louise} and Susanne Malander and Line Bj{\o}rge and Birrer, {Michael J.} and Maarit Anttila and Gabriel Lindahl and Sakari Hietanen and Maria Dimoula and Ulla Peen and Kristine Madsen and Anja Knudsen and Synnove Staff and {Buchner Vinum}, Nicole and Kjeldsen, {Maj Kamille} and Elisabeth Avall-Lundqvist and Maenpaa, {Johanna Unelma}",

year = "2020",

doi = "10.1200/JCO.2020.38.15_suppl.6012",

language = "English",

volume = "38",

pages = "6012--6012",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "15, suppl.",

note = "2020 ASCO Annual Meeting ; Conference date: 29-05-2020 Through 31-05-2020",

}

Mirza, MR, Nyvang, G-B, Lund, B, Christensen, RD, Werner, TL, Malander, S, Bjørge, L, Birrer, MJ, Anttila, M, Lindahl, G, Hietanen, S, Dimoula, M, Peen, U, Madsen, K, Knudsen, A, Staff, S, Buchner Vinum, N, Kjeldsen, MK, Avall-Lundqvist, E & Maenpaa, JU 2020, 'Final survival analysis of NSGO-AVANOVA2/ENGOT-OV24: Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer—A randomized controlled chemotherapy-free study.', Journal of Clinical Oncology, vol. 38, no. 15, suppl., pp. 6012-6012. https://doi.org/10.1200/JCO.2020.38.15_suppl.6012

Final survival analysis of NSGO-AVANOVA2/ENGOT-OV24: Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer—A randomized controlled chemotherapy-free study. / Mirza, Mansoor Raza; Nyvang, Gitte-Betina; Lund, Bente et al.
In: Journal of Clinical Oncology, Vol. 38, No. 15, suppl., 2020, p. 6012-6012.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

TY - ABST

T1 - Final survival analysis of NSGO-AVANOVA2/ENGOT-OV24

T2 - 2020 ASCO Annual Meeting

AU - Mirza, Mansoor Raza

AU - Nyvang, Gitte-Betina

AU - Lund, Bente

AU - Christensen, Rene dePont

AU - Werner, Theresa Louise

AU - Malander, Susanne

AU - Bjørge, Line

AU - Birrer, Michael J.

AU - Anttila, Maarit

AU - Lindahl, Gabriel

AU - Hietanen, Sakari

AU - Dimoula, Maria

AU - Peen, Ulla

AU - Madsen, Kristine

AU - Knudsen, Anja

AU - Staff, Synnove

AU - Buchner Vinum, Nicole

AU - Kjeldsen, Maj Kamille

AU - Avall-Lundqvist, Elisabeth

AU - Maenpaa, Johanna Unelma

PY - 2020

Y1 - 2020

U2 - 10.1200/JCO.2020.38.15_suppl.6012

DO - 10.1200/JCO.2020.38.15_suppl.6012

M3 - Conference abstract in journal

SN - 0732-183X

VL - 38

SP - 6012

EP - 6012

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 15, suppl.

Y2 - 29 May 2020 through 31 May 2020

ER -

Mirza MR, Nyvang G-B, Lund B, Christensen RD, Werner TL, Malander S et al. Final survival analysis of NSGO-AVANOVA2/ENGOT-OV24: Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer—A randomized controlled chemotherapy-free study. Journal of Clinical Oncology. 2020;38(15, suppl.):6012-6012. doi: 10.1200/JCO.2020.38.15_suppl.6012